2021
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AB-836, an HBV Capsid Inhibitor, in Healthy Subjects and Subjects with Chronic HBV Infection

Identification and characterization of barriers to treatment in chronic Hepatitis B (CHB) patients followed by the Canadian Hepatitis B Network

A Randomized Phase 2a, Multicenter, Open-Label, Multiple-Cohort Study Evaluating Regimens Containing Vebicorvir in Subjects with Chronic Hepatitis B Virus Infection

Identification and characterization of barriers to treatment in chronic Hepatitis B (CHB) patients in Ontario

Immunogenicity outcomes in people living with HIV following vaccination for COVID-19 (HIV-COV)

Clinical Practice Outcomes in HCV infected tReatment naive patients with compensatEd cirrhosis treated with 8 weeks of Glecaprevir/PibrentaSvir: A retrospecTive chart review

Phase 2, Double-blind, Randomized, Placebo controlled Study of HepTcell (Adjuvanted FP-02.2) as an Immunotherapeutic Vaccine in Treatment-naïve Patients with Inactive Chronic Hepatitis B (CHB)

Canadian COVID-19 Cohort Study (CCCS): Study of the epidemiology of COVID-19 in Canadian healthcare workers

2020
A Study to Determine Benefits of Hepatitis B Surface Antigen (HBsAg) Loss in a Multiethnic Cohort of Untreated and Treated Patients with Chronic Hepatitis B Infection

Parallel Cohort Study to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis B Virus (B-Clear)

Stop the Spread Ottawa: Analysis of Antibody Neutralization Efficiency and Cellular Immunity to SARS-CoV-2-Positive Individuals Identified in a Surveillance and Convalescence Survey of At-Risk Individuals

COVID-19 Ring-based Prevention trial with Lopinavir/ritonavir

A Phase II, Randomized, Adaptive, Open-Label Platform Trial to Evaluate Efficacy and Safety of Multiple Combination Therapies in Participants with Chronic Hepatitis B

2018
Use of Immune Modulatory Properties of Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity: Proposal for Pilot Clinical Trial

Determination of Clinical and Molecular Properties of Hepatitis B Virus (HBV) in the Context of Concomitant Chronic Hepatitis B and Non-Alcoholic Fatty Liver Disease (NAFLD)

2017
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)

Characterizing Risk Behavior and Reinfection Rates for Successful Programs to Engage Core Transmitters in HCV Elimination (C-RESPECT)

An Observational Epidemiological Study Assessing the Real-World Utilization and Effectiveness of Elbasvir/Grazoprevir (Zepatier®) in Adult Patients with Chronic Hepatitis C (Z-PROFILE)

A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

MK-3682B (MK-5172 + MK-3682 + MK-8408 Fixed Dose Combination (FDC)) in HCV GT1 or GT3 DAA Failures

The Canadian Network on Hepatitis C Clinical research Core: National HCV Registry Protocol (Prospective/Retrospective)

A multi-centre phase III study to evaluate pre-emptive Tenofovir for prevention of hepatitis B virus reactivation in HBsAg negative/anti-HBc positive individuals undergoing anti-CD20-based chemotherapy for Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leu

Cross-Sectional Analysis on the Importance of Hepatitis C Treatment for Women of Child-bearing Potential

A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic HCV Infection Who are on Dialysis for End Stage Renal Disease

2016
A Phase 2, Open-Label Clinical Trial to Study the Efficacy and Safety of 12 weeks of the Combination Regimen of MK-3682 + MK-8408 in Subjects with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 3, 4, 5 or 6 Infection

A Phase 1, Nonrandomized, Multicenter, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment (Mild and Moderate) on the Single-Dose Pharmacokinetics of Lonafarnib Plus Ritonavir in Hepatically Impaired Vs. Healthy Male and Female Subjects

A Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of the V920 (rVSV G-ZEBOV-GP) Ebola Virus Vaccine Candidate in HIV-Infected Adults and Adolescents

A phase IV open-label, multicentre, international trial of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin for people with chronic hepatitis C virus genotype 1 infection and recent injection drug use (D3FEAT)

A Prospective Study of Hepatitis B Virus (HBV) Immunity and Hepatitis B Vaccination in Patients with Non Alcoholic Fatty Liver Disease (NAFLD) in Canada

Canadian Hepatitis B Network

What are the patterns of health and healthcare utilization among people with HIV and HCV infection, in particular retention in, transition between, and attrition from different care settings?

Antiviral-Experienced Subjects with Chronic HCV Infection who Have Not Received an NS5A Inhibitor POLARIS4-A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection who Have Not Received an NS5A Inhibitor

POLARIS 2-A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naïve Subjects with Chronic HCV Infection